Evidence map›Paper›PMID 34439818›Full record

ArticleBiomolecules2021

A Novel Splice Variant of the Inhibitor of Growth 3 Lacks the Plant Homeodomain and Regulates Epithelial-Mesenchymal Transition in Prostate Cancer Cells.

Anna Melekhova, Mirjam Leeder, Thanakorn Pungsrinont, Tim Schmäche, Julia Kallenbach, Marzieh Ehsani, Kimia Mirzakhani, Seyed Mohammad Mahdi Rasa, Francesco Neri, Aria Baniahmad

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Anna MelekhovaInstitute of Human Genetics, Jena University Hospital, 07740 Jena, Germany.
Mirjam LeederDepartment of Adult and Pediatric Urology, Jena University Hospital, 07743 Jena, Germany.
Thanakorn PungsrinontInstitute of Human Genetics, Jena University Hospital, 07740 Jena, Germany.
Tim SchmächeInstitute of Human Genetics, Jena University Hospital, 07740 Jena, Germany.
Julia KallenbachInstitute of Human Genetics, Jena University Hospital, 07740 Jena, Germany.
Marzieh EhsaniInstitute of Human Genetics, Jena University Hospital, 07740 Jena, Germany.
Kimia MirzakhaniInstitute of Human Genetics, Jena University Hospital, 07740 Jena, Germany.
Seyed Mohammad Mahdi RasaLeibniz Institute on Aging, 07745 Jena, Germany.
Francesco NeriLeibniz Institute on Aging, 07745 Jena, Germany.
Aria BaniahmadInstitute of Human Genetics, Jena University Hospital, 07740 Jena, Germany.ORCID 0000-0003-1085-9161
Jena University Hospital · DELeibniz Institute on Aging - Fritz Lipmann Institute (FLI) · DEGerman Cancer Research Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhibitor of growth 3 (ING3) is one of five members of the ING tumour suppressor family, characterized by a highly conserved plant homeodomain (PHD) as a reader of the histone mark H3K4me3. ING3 was reported to act as a tumour suppressor in many different cancer types to regulate apoptosis. On the other hand, ING3 levels positively correlate with poor survival prognosis of prostate cancer (PCa) patients. In PCa cells, ING3 acts rather as an androgen receptor (AR) co-activator and harbours oncogenic properties in PCa. Here, we show the identification of a novel ING3 splice variant in both the human PCa cell line LNCaP and in human PCa patient specimen. The novel ING3 splice variant lacks exon 11, ING3∆ex11, which results in deletion of the PHD, providing a unique opportunity to analyse functionally the PHD of ING3 by a natural splice variant. Functionally, overexpression of ING3Δex11 induced morphological changes of LNCaP-derived 3D spheroids with generation of lumen and pore-like structures within spheroids. Since these structures are an indicator of epithelial-mesenchymal transition (EMT), key regulatory factors and markers for EMT were analysed. The data suggest that in contrast to ING3, ING3Δex11 specifically modulates the expression of key EMT-regulating upstream transcription factors and induces the expression of EMT markers, indicating that the PHD of ING3 inhibits EMT. In line with this, ING3 knockdown also induced the expression of EMT markers, confirming the impact of ING3 on EMT regulation. Further, ING3 knockdown induced cellular senescence via a pathway leading to cell cycle arrest, indicating an oncogenic role for ING3 in PCa. Thus, the data suggest that the ING3Δex11 splice variant lacking functional PHD exhibits oncogenic characteristics through triggering EMT in PCa cells.

Indexed as

Gene Expression Regulation, NeoplasticRNA SplicingCell Line, TumorCell ProliferationCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p21Epithelial-Mesenchymal TransitionHistonesHomeodomain ProteinsHumansMaleProstatic NeoplasmsRNA, Small InterferingSignal TransductionSnail Family Transcription FactorsSpheroids, CellularCDKN1A protein, humanCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p21histone H3 trimethyl Lys4HistonesHomeodomain ProteinsING3 protein, humanRNA, Small InterferingSNAI1 protein, humanSNAI2 protein, humanSnail Family Transcription FactorsTATA-Box Binding ProteinTBP protein, humanTumor Suppressor ProteinsTwist-Related Protein 1ZEB1 protein, humanZinc Finger E-box-Binding Homeobox 1inhibitor of growth 3plant homeodomainprostate cancer

Identifiers

PMID34439818
PMCPMC8392754
OpenAlexW3193074149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.